Monroe Capital (MRCC) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
A special meeting is scheduled for February 21, 2025, to approve a new investment advisory and management agreement due to a change of control at the investment adviser, MC Advisors, following Wendel SE's acquisition of a 75% stake in Monroe.
The new agreement is identical in all material respects to the current agreement, with no changes to management, investment strategy, fee structure, or services provided.
The Board, including all independent directors, unanimously recommends approval, citing continuity in leadership, additional capital for growth, and enhanced fundraising capabilities.
The transaction is expected to close in the first half of 2025, pending regulatory and shareholder approvals.
Voting matters and shareholder proposals
The sole item for shareholder vote is the approval of the new investment advisory and management agreement between the company and MC Advisors.
Approval requires the affirmative vote of a majority of outstanding voting securities as defined by the 1940 Act.
If not approved, an interim agreement may be put in place for up to 150 days while seeking further shareholder approval.
Shareholders may submit proposals for the 2025 annual meeting between October 20 and December 19, 2024.
Board of directors and corporate governance
Four of five board members are independent, and this composition will be maintained for at least three years post-transaction.
The Board reviewed the transaction and agreement at a December 9, 2024 meeting and unanimously recommended approval.
The Board considered service quality, investment performance, costs, economies of scale, and potential conflicts in its evaluation.
Latest events from Monroe Capital
- Both asset sale and merger proposals were approved by a majority of outstanding shares.MRCC
EGM 202613 Mar 2026 - Supplemental distributions and enhanced merger terms were approved to address shareholder concerns.MRCC
Proxy Filing11 Mar 2026 - Supplement updates proxy materials for a proposed transaction, referencing recent filings.MRCC
Proxy Filing6 Mar 2026 - Net investment income and NAV declined year-over-year, with merger expected to unlock value.MRCC
Q4 20255 Mar 2026 - Director election and share sale authorization approved; no shareholder questions raised.MRCC
AGM 20243 Feb 2026 - Adjusted NII rose to $0.31/share, covering the dividend as NAV and leverage declined.MRCC
Q2 20242 Feb 2026 - Shareholders to vote on merger and asset sale, with NAV-based share exchange and fee waiver.MRCC
Proxy Filing20 Jan 2026 - Dividend coverage strong, NAV dipped, non-accruals up, Wendel partnership adds $1B capital.MRCC
Q3 202414 Jan 2026 - Q4 income covered dividends; NAV dipped, but 2025 outlook targets growth and risk discipline.MRCC
Q4 202416 Dec 2025